Vor Biopharma Inc. (VOR)
$
1.52
-0.05 (-3.29%)
Key metrics
Financial statements
Free cash flow per share
-0.9107
Market cap
192.6 Million
Price to sales ratio
52.2404
Debt to equity
0
Current ratio
3.4868
Income quality
0.0683
Average inventory
0
ROE
5.2422
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Vor Biopharma, Inc. is a clinical-stage company that develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is currently advancing its lead product candidate, VOR33, which is in phase 1/2 trials aimed at treating acute myeloid leukemia (AML) and other hematological malignancies. The company’s innovative approach involves eHSCs that lack CD33, a protein prevalent on AML blood cancer cells, enhancing the specificity of treatment. In addition to VOR33, Vor Biopharma's eHSCs are designed to work in conjunction with other targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates, offering a comprehensive therapeutic strategy for blood cancers. The company maintains a collaboration agreement with Akron BioProducts for the development and manufacture of cGMP nucleases. The company incurred an income tax expense of $0.00 indicating its tax obligations. The weighted average number of diluted shares outstanding is 68,705,639.00 reflecting potential dilution effects. Furthermore, the net total of other income and expenses is $4,271,000.00 which showcases the impact of non-core financial activities. Additionally, Vor Biopharma earned an interest income of $4,271,000.00 highlighting its financial investments. The net income ratio stands at 0.00 reflecting the company's profitability margin. The company's stock presents an attractive opportunity, as it is affordable at $1.50 making it suitable for budget-conscious investors. It enjoys an average trading volume of 19,045,250.00 indicating moderate liquidity, which can be appealing for active traders. With a market capitalization of $192,558,160.00 Vor Biopharma is categorized as a small-cap player within the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. By operating in the Healthcare sector, Vor Biopharma is driving innovation and growth, addressing critical needs within the oncology space and providing new possibilities for cancer treatment.
Is Vor Biopharma Inc. (VOR) a good investment?
Investing in Vor Biopharma Inc. (VOR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Vor Biopharma Inc. (VOR)'s stock forecast?
Analysts predict Vor Biopharma Inc. stock to fluctuate between $0.13 (low) and $3.29 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Vor Biopharma Inc.'s market capitalization?
As of 2025-09-17, Vor Biopharma Inc.'s market cap is $192,558,160, based on 126,683,000 outstanding shares.
How does Vor Biopharma Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Vor Biopharma Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Vor Biopharma Inc. (VOR) stock?
To buy Vor Biopharma Inc. (VOR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VOR. Place an order (Market, Limit, etc.).
What is the best time to invest in Vor Biopharma Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Vor Biopharma Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.70 | Growth: -2.86%.
Where can I find Vor Biopharma Inc.'s investor relations reports?
Visit https://www.vorbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Vor Biopharma Inc.?
You can explore historical data from here
What is the all-time high and low for Vor Biopharma Inc. stock?
All-time high: $18.52 (2021-11-05) | All-time low: $0.13 (2025-05-09).
What are the key trends affecting Vor Biopharma Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
YANTAI, China , Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gravis (gMG) was selected as an oral presentation at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting.
globenewswire.com
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, being held October 29 to November 1, 2025, at the Hilton San Francisco Union Square in San Francisco, California.
globenewswire.com
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.
benzinga.com
Vor Bio VOR stock is trading higher on Wednesday with a session volume of 10.83 million compared to the average volume of 17.99 million, as per data from Benzinga Pro.
globenewswire.com
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), achieved the primary endpoint in a Phase 3 clinical study in China evaluating telitacicept in adults with primary Sjögren's disease.
globenewswire.com
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities
globenewswire.com
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development
globenewswire.com
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
benzinga.com
H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company's “rebirth” following the in-licensing of telitacicept.
zacks.com
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
See all news
